Trials / Completed
CompletedNCT00446290
Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer
A Phase I Study of Docetaxel, Capecitabine and Oxaliplatin (DXO) in Patients With Advanced Stomach Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Considering synergism between docetaxel (D), capecitabine (X), and oxaliplatin (O) and favourable toxicity profile of oxaliplatin over cisplatin, it is to be expected that combination of docetaxel, capecitabine, and oxaliplatin (DXO) will be more effective than other regimens and feasible in advanced gastric cancer. DXO regimen can be also easily administered on out-patient setting. However, so far, DXO combination has not been tried in advanced gastric cancer. The investigators will determine maximum tolerated dose of DXO regimen in this phase I study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel, Capecitabine and Oxaliplatin |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2007-03-12
- Last updated
- 2020-01-18
- Results posted
- 2015-07-28
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00446290. Inclusion in this directory is not an endorsement.